TheraRadar
Landscape / Endocrine
Data updated: Jun 28, 2026

Hyperthyroidism Clinical Trial Landscape

Hyperthyroidism is being studied across 27 clinical trials registered since 2008, with 11 programs currently active. The competitive pipeline includes 4 active Phase 3 trials, 2 active Phase 2 trials, and 3 active Phase 1 trials.

Top industry sponsors include Biohaven Therapeutics Ltd., argenx, Merida Biosciences.

Trial activity

11 active / 27 total since 2008
Active by phase 4 Ph3 / 8 2 Ph2 / 6 3 Ph1 / 5 2 Ph4 / 8

Sponsor activity

Who is running trials now — green active, blue completed, red failed/terminated.

Sorted by active Active Done Failed
Biohaven Therapeutics Ltd. 2 0 0
argenx 2 0 0
Merida Biosciences 1 0 0
Changchun GeneScience Pharmaceutical Co., Ltd. 1 0 0

How the field has grown

New-trial starts peaked in 2019 (4 registered); 2025 saw 4. The right-hand chart shows median Phase 3 enrollment by start year — the number in parentheses is that year's Phase 3 trial count (6 in total), so single-trial years (and years with no Phase 3 starts) are obvious. Both are by trial start date; the current year is partial.

New trials started by year

2016
1
2017
1
2018
1
2019
4
2020
0
2021
3
2022
1
2023
2
2024
0
2025
4
2026
4

TheraRadar.com

Median Phase 3 enrollment by start year

2016 (0)
0
2017 (0)
0
2018 (0)
0
2019 (1)
36
2020 (0)
0
2021 (2)
111
2022 (0)
0
2023 (0)
0
2024 (0)
0
2025 (0)
0
2026 (3)
230

TheraRadar.com

Full trial pipeline

Every active and completed trial across Phase 1–4, with enrollment analytics. Sortable, filterable, exportable with Pro.

NCT07570316 NOT YET RECRUITING
A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease
argenx n=230
NCT04856488 RECRUITING
Preoperative Lugol's Solution in Graves' Disease and Toxic Nodular Goiter
Jan Calissendorff n=182
NCT07596849 NOT YET RECRUITING
A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease.
argenx n=230
NCT07661056 RECRUITING
Study to Determine if BHV-1300 is Effective and Safe in Adults With Graves' Disease
Biohaven Therapeutics Ltd. n=300
NCT05142904 TERMINATED
Radiofrequency Ablation Versus I-131 for Solitary Autonomous Thyroid Nodules
Rijnstate Hospital n=40
NCT04080505 TERMINATED
Does Potassium Iodide (SSKI) Reduce Vascularity in Graves' Thyroidectomy?
Columbia University n=29
NCT05118542 COMPLETED
Effect of Hyperthyroidism and Its Treatment in Graves' Disease to Early Marker of Atherosclerosis
Indonesia University n=36
NCT01295333 COMPLETED
Assessing the Impact of the Early and Systematic Hormonal Replacement After Radio-isotopic Ablation of Graves'hyperthyroïdism on Quality of Life, Efficiency and Tolerance
Assistance Publique Hopitaux De Marseille n=200

Full Hyperthyroidism Pipeline

Every trial across Phase 1–4, plus enrollment analytics. Sortable, filterable, exportable.

Unlock with Pro

Data: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only